Navigation Links
Cambrex Reports Third Quarter 2008 Results
Date:11/4/2008

EAST RUTHERFORD, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports third quarter 2008 results for the period ended September 30, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

-- Sales increased 3.2% (-1.7% excluding foreign currency) compared to

third quarter 2007.

-- Adjusted EBITDA for the quarter was up $1.7 million to $11.4 million

versus $9.7 million last year.

-- Debt, net of cash was $92.0 million at the end of third quarter 2008.

Excluding the impact of foreign exchange, debt, net of cash decreased

$2.6 million during the third quarter.

Basis of Reporting

As previously reported, Cambrex sold its Bioproducts and Biopharma businesses (the "Bio Businesses") to Lonza for $463.9 million in February 2007. Discontinued Operations in the 2007 financial statements include the results of operations of the Bio Businesses through the date of sale as well as the corresponding gain on sale.

The Company has provided a reconciliation from adjusted amounts to GAAP amounts at the end of this press release. Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

Third Quarter 2008 Operating Results - Continuing Operations

Third quarter 2008 sales of $56.5 million were 3.2% higher than the third quarter 2007 and 1.7% lower excluding the effect of foreign currency. Comparing the current quarter to the same quarter last year, excluding the currency impact, custom development revenues declined due to weaker demand and customer and manufacturing delays in certain projects, and lower shipments of products based on the Company's proprietary technologies due to timing of order patterns. Certain active pharmaceutical ingredients ("APIs") experienced price declines compared to the same quarter last year, with the largest impact resulting from the 2007 renegotiation of a long-term contract to manufacture the Company's largest API. Volumes associated with feed additives were lower due largely to the Company's late 2007 decision to exit this business. These declines were partially offset by higher sales of generic APIs, particularly certain controlled substances.

Third quarter 2008 Gross Margin decreased to 28.7% of sales from 33.8% during the third quarter 2007, with foreign currency favorably impacting gross margin by 2.9%. Unfavorable product mix, lower pricing on the Company's largest API, higher raw material costs, and higher costs associated with the validation of the new API finishing facility at the Milan, Italy site, were the main drivers of the lower margins.

Operating Profit increased to $4.5 million in the third quarter 2008 from $3.5 million in the third quarter 2007. Adjusted Operating Profit was $5.7 million, or 10.1% of sales, compared to $4.8 million, or 8.8% of sales for the third quarter last year. Adjusted EBITDA increased to $11.4 million, or 20.2% of sales, compared to $9.7 million, or 17.8% of sales last year. The increases in both Adjusted Operating Profit and Adjusted EBITDA were driven primarily by lower corporate headquarters expenses, lower Selling, General and Administrative ("SG&A") expenses, and lower research and development expenses, partially offset by the lower gross profits described above and the negative impact of foreign currency on operating expenses.

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with the increases in Operating Profit and Adjusted EBITDA for the quarter. While general business conditions have impacted the number and timing of new custom development projects, especially those in the early clinical stages of development, the Company has a strong pipeline of late- stage Phase III projects. In addition, we continue to see solid growth in our controlled substances products. Softer market conditions, along with the previously reported impact of a customer recall, have resulted in lower than expected year-to-date results and ultimately a moderate downward revision in our full year earnings guidance.

"We are nearing completion of our new mid-scale API manufacturing facility at our Swedish operation, which is expected to be on line in early 2009, and production has started in a portion of our state of the art API finishing facility in Milan, Italy, with the remainder in the later stages of validation. Along with our new high potency development center in Iowa, the completion of these projects cap a three year period of higher than normal capital investments and position us well for future growth.

"We were pleased with the positive cash generation in the third quarter net of the impact of foreign exchange. We will continue to aggressively cut costs and focus on increasing cash flow in 2009 and beyond.

"We have nearly three and a half years remaining on our $200 million revolving credit facility and believe that cash flows from operations, along with funds available from this facility, will provide more than enough capital to execute our plan over the next few years of aggressively growing sales of products based on our proprietary drug delivery and tastemasking technologies, controlled substances, new generic APIs, and the transition of late stage clinical projects to long term supply agreements."

Third Quarter 2008 Operating, Interest and Tax Expenses - Continuing Operations

SG&A Expenses in the third quarter 2008 were $8.8 million compared to $10.7 million in the same period last year. The decrease is a result of corporate headquarters restructuring activities and expense reductions within the Company's manufacturing facilities, partially offset by the negative impact of foreign currency.

Research and Development ("R&D") Expenses for the third quarter 2008 were $1.8 million compared to $3.1 million in the third quarter 2007. The decrease is primarily due to the Company's decision in 2007 to consolidate its New Jersey technical center into the Company's Iowa facility in order to create increased operating efficiencies. Cambrex also utilized certain R&D personnel on custom development projects resulting in these costs being classified as Cost of Goods Sold.

Strategic Alternative and Restructuring Costs totaling $1.2 million in the third quarter 2008 include $0.3 million of costs related to the consolidation of operations at the New Jersey technical center into the Iowa facility, and $0.9 million of expense related to severance, change-in-control liabilities, and the ongoing project to streamline the Company's legal entity structure in order to lower operating costs and increase tax efficiency.

Net Interest Expense in the third quarter 2008 was $1.0 million compared to $1.1 million in the third quarter 2007. The Company capitalized interest of $0.5 million on long-term projects in the third quarter of 2008.

The effective tax rate for the third quarter 2008 was 9.8% and the Provision for Income Taxes totaled $0.3 million. Favorable resolution of certain tax issues resulted in a benefit to tax expenses of $1.5 million during the third quarter 2008. The Company's effective tax rates have been and are expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits for U.S. GAAP purposes in certain jurisdictions where there has been a recent history of losses, primarily the U.S.

Third Quarter 2008 Capital Expenditures and Depreciation

Capital expenditures and depreciation for the third quarter 2008 were $5.0 million and $5.7 million compared to $10.2 million and $4.9 million in the third quarter 2007, respectively. The decrease in capital spending is largely due to spending on an API purification facility at the Milan facility in the third quarter of 2007 for which the majority of spending has since been completed.

Guidance

The Company expects that sales, net of the impact of foreign currency, will decline between 3% and 5% in 2008 compared to 2007. Adjusted EBITDA for 2008 is now expected to be between $50 and $53 million.

Restructuring and Strategic Alternatives Costs are expected to be approximately $3.8 million, which includes higher-than expected costs related to the legal entity restructuring completed during the third quarter of 2008 and charges expected during the fourth quarter of 2008 related to additional cost reductions at the Company's corporate headquarters (expected to reduce future administrative expenses by approximately $0.5 million annually). The legal entity restructuring will reduce annual administrative expenses by approximately $0.3 million and will reduce income tax expense in 2008 by approximately $1.0 million. The Company continues to experience delays in sub-leasing the recently closed New Jersey technical center.

For 2008, capital expenditures are expected to be approximately $32 to $34 million and depreciation is expected to be $21 to $22 million.

Other Matter

The Company previously reported that one of the Company's customers recalled a product in the U.S. in March of 2008, and that this would result in a reduction of approximately $6.0 million in revenue compared to original 2008 guidance. The Company continues to expect this level of reduction and the impact of this expectation is included in the full year 2008 guidance discussed above.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the third quarter 2008 Form 10-Q is filed with the SEC.

Conference Call and Webcast

The Conference Call to discuss third quarter 2008 earnings will begin at 8:30 a.m. Eastern Time on Wednesday, November 5, 2008 and last approximately 45 minutes. Those wishing to participate should call 1-888-634-4003 for domestic and +1-706-634-6653 for international. Please use the pass code 68710081 and call approximately 10 minutes prior to start time. A webcast is available from the Investors section on the Cambrex website located at http://www.cambrex.com and can be accessed for 30 days following the conference call. A telephone replay of the conference call will be available through Wednesday, November 12, 2008 by calling 1-800-642-1687 for domestic and +1-706-645-9291 for international. Please use the pass code 68710081 to access the replay.

Forward Looking Statements

This news release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions are used in connection with any discussion of future financial or operating performance. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in the Company's periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and the accuracy of the Company's current estimates with respect to its earnings and profits for tax purposes in 2007. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which new factors will arise. In addition, we cannot assess the impact of each factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors and security holders are cautioned to review the Cambrex 2007 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other subsequent filings with the U.S. Securities and Exchange Commission, including Current Reports on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule APIs, advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com.

CAMBREX CORPORATION

Statement of Profit and Loss

For the Quarters Ended September 30, 2008 and 2007

(in thousands)

2008 2007

% of % of

Amount Sales Amount Sales

Gross Sales $56,508 100.0% $54,742 100.0%

Allowances and Rebates 193 0.3% 227 0.4%

Net Sales 56,315 99.7% 54,515 99.6%

Other Revenues 1,977 3.5% 99 0.2%

Net Revenues 58,292 103.2% 54,614 99.8%

Cost of Goods Sold 42,057 74.5% 36,093 66.0%

Gross Profit 16,235 28.7% 18,521 33.8%

Operating Expenses

Selling, General and

Administrative Expenses 8,767 15.5% 10,669 19.5%

Research and Development

Expenses 1,772 3.1% 3,062 5.6%

Restructuring Expenses 321 0.6% 451 0.8%

Strategic Alternative Costs 833 1.5% 866 1.6%

Total Operating Expenses 11,693 20.7% 15,048 27.5%

Operating Profit 4,542 8.0% 3,473 6.3%

Other Expenses:

Interest Expense, net 956 1.7% 1,069 1.9%

Other Expense, net 485 0.8% 548 1.0%

Income Before Income Taxes 3,101 5.5% 1,856 3.4%

Provision for Income Taxes 304 0.6% 4,592 8.4%

Income/(Loss) from Continuing

Operations $2,797 4.9% $(2,736) -5.0%

Income from Discontinued

Operations, Net of Tax - 0.0% 4,229 7.7%

Net Income $2,797 4.9% $1,493 2.7%

Basic Earnings/(Loss) per Share

Income/(Loss) from Continuing

Operations $0.10 $(0.09)

Income from Discontinued

Operations, Net of Tax $- $0.14

Net Income $0.10 $0.05

Diluted Earnings/(Loss) per Share

Income/(Loss) from Continuing

Operations $0.10 $(0.09)

Income from Discontinued

Operations, Net of Tax $- $0.14

Net Income $0.10 $0.05

Weighted Average Shares Outstanding

Basic 29,163 28,934

Diluted 29,178 28,934

CAMBREX CORPORATION

Statement of Profit and Loss

For the Nine Months Ended September 30, 2008 and 2007

(in thousands)

2008 2007

% of % of

Amount Sales Amount Sales

Gross Sales $184,440 100.0% $182,820 100.0%

Allowances and Rebates 1,137 0.6% 1,001 0.5%

Net Sales 183,303 99.4% 181,819 99.5%

Other Revenues 1,792 1.0% 864 0.5%

Net Revenue 185,095 100.4% 182,683 100.0%

Cost of Sales 127,120 69.0% 115,829 63.4%

Gross Profit 57,975 31.4% 66,854 36.6%

Operating Expenses

Selling, General and

Administrative Expenses 31,511 17.0% 36,572 20.1%

Research and Development Expenses 5,945 3.2% 8,623 4.7%

Restructuring Expenses 1,469 0.8% 4,034 2.2%

Strategic Alternative Costs 1,408 0.8% 28,560 15.6%

Total Operating Expenses 40,333 21.8% 77,789 42.6%

Operating Profit/(Loss) 17,642 9.6% (10,935) -6.0%

Other Expenses/(Income):

Interest Expense/(Income), net 2,302 1.3% (1,341) -0.7%

Other Expenses, net 459 0.2% 930 0.5%

Income/(Loss) Before Income Taxes 14,881 8.1% (10,524) -5.8%

Provision for Income Taxes 6,002 3.3% 4,200 2.3%

Income/(Loss) from Continuing

Operations $8,879 4.8% $(14,724) -8.1%

Income from Discontinued

Operations, Net of Tax - 0.0% 223,707 122.4%

Net Income $8,879 4.8% $208,983 114.3%

Basic Earnings/(Loss) per Share

Income/(Loss) from Continuing

Operations $0.31 $(0.52)

Income from Discontinued

Operations, Net of Tax $- $7.83

Net Income $0.31 $7.31

Diluted Earnings/(Loss) per Share

Income/(Loss) from Continuing

Operations $0.31 $(0.52)

Income from Discontinued

Operations, Net of Tax $- $7.83

Net Income $0.31 $7.31

Weighted Average Shares Outstanding

Basic 29,096 28,575

Diluted 29,101 28,575

CAMBREX CORPORATION

Reconciliation of Gross Sales, Gross Profit & Operating Profit

For the Quarters and Nine Months Ended September 30, 2008 and 2007

(in thousands)

Third Quarter 2008

Operating

Gross Gross Profit/

Sales Profit GP% (Loss) OP%

Pre-Corporate Results Before

Strat. Alt. & Restructuring

Expenses $56,508 $16,235 28.7% $8,017 14.2%

Corporate Results - - (2,286)

Adjusted Operating Profit 5,731 10.1%

Strat. Alt. & Restructuring

Expenses (1,154)

Equity Modification for

Former Executive (35)

As Reported $56,508 $16,235 28.7% $4,542 8.0%

Third Quarter 2007

Gross Gross Operating

Sales Profit GP% Profit/

(Loss) OP%

Pre-Corporate Results Before

Strat. Alt. & Restructuring

Expenses $54,742 $18,521 33.8% $8,792 16.1%

Corporate Results - - (4,002)

Adjusted Operating Profit 4,790 8.8%

Strat. Alt. & Restructuring

Expenses (1,317)

As Reported $54,742 $18,521 33.8% $3,473 6.3%

Nine Months 2008

Gross Gross Operating

Sales Profit GP% Profit/

(Loss) OP%

Pre-Corporate Results Before

Strat. Alt. & Restructuring

Expenses $184,440 $57,975 31.4% $30,627 16.6%

Corporate Results - - (9,476)

Adjusted Operating Profit 21,151 11.5%

Strat. Alt. & Restructuring

Expenses (2,877)

Equity Acceleration &

Modification for Former

Executive (632)

As Reported $184,440 $57,975 31.4% $17,642 9.6%

Nine Months 2007

Gross Gross Operating

Sales Profit GP% Profit/

(Loss) OP%

Pre-Corporate Results Before

Strat. Alt. & Restructuring

Expenses $182,820 $66,854 36.6% $37,783 20.7%

Corporate Results - - (16,124)

Adjusted Operating Profit 21,659 11.8%

Strat. Alt. & Restructuring

Expenses (32,594)

As Reported $182,820 $66,854 36.6% $(10,935) -6.0%

Third Third Nine Nine

Quarter Quarter Months Months

2008 2007 2008 2007

Pre-Corporate Operating

Profit Before Strat. Alt. &

Restructuring Expenses $8,017 $8,792 $30,627 $37,783

Corporate Results (2,286) (4,002) (9,476) (16,124)

Depreciation and

Amortization 5,683 4,934 16,115 14,579

Adjusted EBITDA $11,414 $9,724 $37,266 $36,238

CAMBREX CORPORATION

Consolidated Balance Sheet

As of September 30, 2008 and December 31, 2007

(in thousands)

September 30, December 31,

Assets 2008 2007

Cash and Cash Equivalents $29,173 $38,488

Trade Receivables, net 26,775 45,003

Inventories, net 69,506 61,440

Prepaid Expenses and Other Current Assets 15,803 20,104

Total Current Assets 141,257 165,035

Property, Plant and Equipment, Net 166,001 165,657

Goodwill 35,565 35,552

Other Non-Current Assets 5,702 7,218

Total Assets $348,525 $373,462

Liabilities and Stockholders' Equity

Accounts Payable $18,448 $26,185

Accrued Expenses and Other Current

Liabilities 42,964 69,702

Total Current Liabilities 61,412 95,887

Long-term Debt 121,000 101,600

Deferred Tax Liabilities 18,269 19,086

Accrued Pension and Postretirement

Benefits 28,151 32,104

Other Non-Current Liabilities 17,674 22,728

Total Liabilities $246,506 $271,405

Stockholders' Equity $102,019 $102,057

Total Liabilities and Stockholders'

Equity $348,525 $373,462


'/>"/>
SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):